HELSINKI, Jan. 5, 2024 /PRNewswire/ -- Nanoform Finland Plc ("Nanoform"), the medicine performance enhancing company, today announced it had completed the First Subject First Visit (FSFV) in a trial ...
Nanoform has completed the First Subject First Visit in a trial evaluating the relative bioavailability of its nanotechnology-enhanced enzalutamide. Finnish medicine performance enhancing company, ...
The aim of the study was to measure the relative bioavailability of labeled pteroylglutamic acid (13C5-PteGlu) from a pectin-coated fortified rice in vivo to measure any effect of the edible coating ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback